LVM | LVCI | LVEDV | LVSV | |||||
---|---|---|---|---|---|---|---|---|
β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | |
Initial analysis (= Table 2): separate, fullya adjusted models as in the main analysis | ||||||||
VAT | – | 0.11 (0.07; 0.15) | < 0.001 | − 6.70 (− 8.84; − 4.55) | < 0.001 | − 3.91 (− 5.32; − 2.50) | < 0.001 | |
SAT | – | – | – | − 1.75 (− 3.66; 0.16) | 0.07 | |||
PDFFhepatic | – | 0.06 (0.02; 0.09) | 0.001 | − 3.23 (− 5.03; − 1.44) | < 0.001 | − 2.20 (− 3.37; − 1.04) | < 0.001 | |
Sensitivity analysis 1: separate, fullyb adjusted models with a fixed set of typical cardiovascular risk factors | ||||||||
VAT | – | 0.13 (0.09; 0.16) | < 0.001 | − 7.04 (− 9.12; − 4.97) | < 0.001 | − 4.38 (− 5.76; − 3.01) | < 0.001 | |
SAT | – | – | – | − 1.66 (− 3.62; 0.29) | 0.10 | |||
PDFFhepatic | – | 0.07 (0.03; 0.10) | < 0.001 | − 3.54 (− 5.35; − 1.74) | < 0.001 | − 2.47 (− 3.66; − 1.29) | < 0.001 | |
Sensitivity analysis 2: separate, fullyc adjusted models with a fixed set of typical cardiovascular risk factors and a replacement of the definition of hypertension | ||||||||
VAT | – | 0.12 (0.08; 0.15) | < 0.001 | − 6.79 (− 8.88; − 4.7) | < 0.001 | − 4.22 (− 5.59; − 2.85) | < 0.001 | |
SAT | – | – | – | − 1.49 (− 3.41; 0.43) | 0.13 | |||
PDFFhepatic | – | 0.06 (0.02; 0.09) | 0.001 | − 3.30 (− 5.13; − 1.48) | < 0.001 | − 2.32 (− 3.51; − 1.14) | < 0.001 |